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ABSTRACT
Hypertension is a common but frequently overlooked adverse
effect of erythropoietin (EPO) therapy. Underreporting of hyper-
tension with EPO is likely due to either more aggressively manag-
ing hypertension through the prescription of antihypertensive
drugs or closer attention to dry weight. The purpose and focus of
this review is to critically evaluate the mechanisms of EPO-
induced hypertension. Preclinical data are considered first, fol-
lowed by clinical data where available. Mediated by a variety of
molecules, there is an imbalance in the vascular tone favoring net
vasoconstriction that mediates EPO-induced hypertension.
Animal studies show the primary importance of chronic kidney
disease in the genesis of EPO-induced hypertension. Preclinical
studies show deranged regulation of the nitric oxide, endothelins
and porstanoids and the sympathoadrenal and renin–
angiotensin pathways as causes of EPO-induced hypertension.
Human studies suggest that EPO administration is also associated
with increased responsiveness to catecholamines and angiotensin
II on vascular tissue; in addition, hypoxia-induced vasodilation
may be impaired in those with EPO-induced hypertension.
There is little evidence for EPO as a direct vasoconstrictor or its
effect on blood viscosity as a mechanism of EPO-induced hyper-
tension. EPO-induced hypertension, at least in part, appears to be
independent of an increase in hemoglobin, because experiments
show that hemoglobin may be increased by EPO without an
increase in blood pressure (BP) by simply treating the animals
with EPO-binding protein and that treatment with EPO in the
setting of iron deficiency may not increase hemoglobin but may
still increase BP. However, experimental data are not consistent
across studies and better mechanistic designs are needed, espe-
cially in patients with chronic kidney disease, to dissect the pre-
cise mechanism of EPO-induced hypertension. Animal studies
suggest that hypoxia-inducible factor stablizers may induce
hypertension by provoking calcification and augmenting chronic
intermittent hypoxia as occurs in sleep apnea. Others show that
there may be an antihypertensive effect via kidney repair.
Whether these drugs will alter the risk of hypertension compared
with EPO remains to be seen.
Keywords: anemia, erythropoietin, HIF stablizers, hyperten-
sion, nitric oxide
Hypertension is a common but frequently overlooked adverse
effect of erythropoietin (EPO) therapy [1–6]. Underreporting
of hypertension with EPO is likely due to either more aggres-
sively managing hypertension through the prescription of anti-
hypertensive drugs, closer attention to dry weight [7, 8] or lack
of ambulatory blood pressure (BP) measurements [9]. The pur-
pose and focus of this review is to critically evaluate the mecha-
nisms of EPO-induced hypertension. Preclinical data are
considered first, followed by clinical data where available.
IMPORTANCE OF CHRONIC KIDNEY
DISEASE (CKD) IN EPO-INDUCED
HYPERTENSION
The first study to show that CKD was an important determinant
for EPO-induced hypertension was reported from France in
1995 [10]. Male Wistar rats underwent subtotal nephrectomy at
6 weeks of age, were allowed to recover for 6 weeks and were
then treated for 3 weeks with either vehicle or EPO. Time con-
trols were sham-operated animals that did not undergo nephrec-
tomy and were treated with either vehicle or EPO. As expected,
subtotal nephrectomy in animals increased plasma creatinine
and systolic BP and induced a decrease in hematocrit. Treatment
with EPO provoked a significant increase in hematocrit regard-
less of nephrectomy. EPO treatment increased systolic BP signif-
icantly in the nephrectomized group by 37.5 6 11 mmHg.
There was no significant increase in systolic BP in the
nonnephrectomized EPO-treated or vehicle-treated rats.
Furthermore, no relationship was seen between the change in
hematocrit and the change in systolic BP [10]. Using a very simi-
lar design as above, a 1997 study from Quebec confirmed the
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central importance of reduced renal mass in the development of
hypertension [11]. EPO had no effect on BP in the control rats
despite an increase in hematocrit in rats without nephrectomy,
yet had a large effect in those with a nephrectomy.
The subtotal nephrectomy model provides a consistent
observation for both studies in that by itself—over the time
course studied—it did not provoke hypertension. Furthermore,
there was no increase in BP in the EPO-treated sham-operated
animals. It required both subtotal nephrectomy and EPO to
provoke hypertension. Whether nephrectomy activated the
renin–angiotensin system, caused volume excess or caused
endothelial dysfunction to induce hypertension was not exam-
ined in these studies, but these possibilities were subsequently
explored in other models and will be discussed further below.
Human observations are consistent with animal data.
Although EPO is abused by some athletes to enhance perform-
ance, hypertension or hypertensive crises are not reported.
Similarly, the incidence of hypertension in zidovudine-treated
human immunodeficiency virus–positive anemic patients or
among those undergoing cancer chemotherapy is low.
However, EPO-induced hypertension is very common among
those with CKD, including those on dialysis [6].
HEMOPOIETIC VERSUS
HYPERTENSIONOGENIC EFFECTS OF EPO
Whether BP tracks with hemoglobin or not remains controver-
sial. In a 1988 report, among anemic rats with reduced renal
mass, preventing anemia of renal failure with EPO aggravated
systemic hypertension [12]. In contrast, a low-iron diet that
maintained hemoglobin at a lower level prevented the develop-
ment of hypertension, hyperfiltration, glomerulosclerosis and
proteinuria [12]. In more recent animal experiments, hyperten-
sion did not track with an increase in hemoglobin [13]. If EPO
is administered to anemic animals with chronic renal failure,
but hemoglobin is kept stable by feeding an iron-deficient diet,
hypertension still occurs. In blood vessels harvested from these
animals treated with EPO, vasodilatory responses to nitric oxide
(NO) donors were impaired but response to several vasocon-
strictors was normal. Among patients on long-term hemodialy-
sis, treatment with iron to increase hemoglobin was not
associated with parallel increases in BP [14].
Human data are similarly inconclusive. Some studies show
that although an increase in hemoglobin is dose dependent, an
increase in BP is not [1, 15]. On the other hand, during the first
5 weeks of administration of EPO the change in hemoglobin
concentration was directly related to an increase in diastolic BP
(r¼ 0.42, P< 0.001) [3].
To understand the hypertensionogenic effects of EPO, con-
sideration of the biology of the EPO receptor expressed in the
nonhemopoietic tissues is needed.
EPO RECEPTOR AND ITS RELEVANCE TO
EPO-INDUCED HYPERTENSION
Mutation of EPO receptor is lethal in utero [16]. However, EPO
receptor null mice can survive simply by expressing the EPO
receptor in the hemopoietic tissue only [16]. Despite the lack of
the EPO receptor in the endothelium, heart and brain, these mice,
somewhat surprisingly, develop normally. Using genetic engi-
neering to rescue EPO receptor null mice, two groups of mice
were created with varying amounts of EPO receptor expressed in
the hemopoietic tissue [16]. In one group, the expression of EPO
receptor was 40% of normal and in the second group was 120%
of normal. As expected, the circulating EPO level was higher
when the EPO receptor was lower. However, contrary to expecta-
tions, in response to induced anemia the time to peak plasma
EPO concentrations was delayed in both groups of mice. This
suggests that the extra-hemopoietic EPO receptor may play an
important role in the regulation of plasma EPO concentration.
There is substantial evidence that blood vessels express the
EPO receptor. In a 1994 report, mRNA for the EPO receptor
was identified in human umbilical vein endothelial cells [17].
These endothelial cells lacked erythroid precursors because they
lacked the a-globin and c-globin chains associated with hemo-
globin. Furthermore, antibodies to the extracellular portion of
the EPO receptor stained the vascular endothelium of the pla-
centa and the umbilical cord. Cultured endothelial cells prolifer-
ate in response to EPO [18, 19]. The ability to proliferate is seen
at concentrations of EPO as low as 1 U/mL [19], which is often
achieved with intravenous administration of the drug [20]. The
ability of human umbilical vein endothelial cells to migrate is
also induced by EPO [19].
A series of studies performed by investigators in Japan
among mice expressing EPO receptor in only the hemopoietic
tissue demonstrate the importance of EPO receptor expression
outside hemopoietic tissue [16] such as heart, lungs and the
limbs [21]. Experiments in these mice lacking the EPO receptor
outside hemopoietic tissue display several cardiac, pulmonary
and vascular anomalies as follows: (i) Following coronary liga-
tion, compared with wild-type mice, there was greater infarct
size, due in part to accelerated cardiomyocyte apoptosis [22].
(ii) When pressure overload was induced by aortic banding,
there was greater cardiac dilatation and impairment in cardiac
contractility, due in part to reduced vascular endothelial growth
factor expression and reduced myocardial capillary density
[23]. In response to hypoxia, there was an increased risk of the
development of pulmonary hypertension due to reduced mobi-
lization of the endothelium progenitor cells [24]. (iv) In
response to hind-limb ischemia, there was abrogation of the
expression of vascular endothelial growth factor and its recep-
tor, impairment in the recruitment of endothelial progenitor
cells and bone marrow–derived proangiogenic cells and thereby
reduced neovascularization [25].
Some data suggest that the effects on hemopoiesis and vaso-
constriction may be mediated by different epitopes on the EPO
molecule [26]. Rodents treated with EPO, when also treated
with an EPO binding protein, had an increase in hemoglobin
but their BP did not change. Furthermore, treatment of the
above animals with the EPO binding protein and an antibody
to this protein increased hemoglobin but did not change BP.
These data suggest that the BP increasing effect of EPO and the
hemopoietic effect of the EPO molecule may be mediated by
different parts of the samemolecule.
EPO can also be engineered by targeting it more specifically
to the hemopoietic EPO receptor and reducing its ability to
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bind to nonhemopoietic tissues [27]. A synthetic EPO molecule
has been created that interacts minimally with the EPO
receptor [27]. To selectively target EPO to the hemopoietic
tissue, it was tethered to an antibody that specifically binds
glycophrin A, which is highly expressed on red blood cells [27].
Compared with wild-type mice, when this new molecule was
given to mice carrying the human glycophorin A gene, the half-
life of engineered EPO was prolonged, reticulocyte response
was augmented and platelet effects were minimized [27]. The
authors speculate that EPO receptor expression on maturing
megakaryocytes may create an off-target prothrombotic state.
In their study, since the total platelet count and reticulated
platelets were both reduced in comparison to darbepoietin, the
new molecule may reduce the risk of thrombotic side effects.
The promise of an engineered EPO with less BP raising effect
has yet to be realized.
MOLECULAR MECHANISMS OF
EPO-INDUCED HYPERTENSION
The mechanisms of EPO-induced hypertension are incom-
pletely understood. Figure 1 summarizes putative mediators
and their effects on BP are discussed further.
Evidence against direct effect of EPO on vascular
smooth muscle or endothelium
Among untreated patients with essential hypertension,
serum EPO concentration correlates with both systemic
vascular resistance and 24-h ambulatory BP [28]. This has led
to speculation that EPO may have direct vasoconstrictive
effects. In order to interpret the results of cell culture studies, it
is important to compare the plasma concentrations of EPO
achieved after a bolus dose in humans with that used in
preclinical studies. A study describing the pharmacokinetics of
EPO in hemodialysis patients notes that the peak concentration
of EPO when given as an intravenous bolus injection was 0.768
U/mL with 50 U/kg EPO and 2.434 U/mL with 150 U/kg
EPO [20].
In 1991, a group of investigators from Muenster, Germany
demonstrated that resistance arterioles from the kidneys and
intestine could be made to vasoconstrict when exposed to EPO
in doses ranging from 10 to 200 U/mL [29]. In 1993 the same
group demonstrated that intracellular calcium is increased in
cultured vascular smooth muscle cells in a dose-dependent
manner upon incubation with EPO [30]. The vascular smooth
muscle cells were incubated with 100 U/mL or 250 U/mL EPO.
It should be noted that these concentrations of EPO are 100–
200-fold higher than the peak concentrations achieved with
intravenous EPO administration [20]. The physiological and
clinical relevance of these observations is therefore unclear.
In humans, EPO by itself does not appear to have any effect
on vasoconstriction. In a double-blind cross-over study in nine
hemodialysis patients, Hon et al. [31] administered either EPO
or saline intravenously. BP was measured every 5 min for
60 min following treatment. Between treatments, no differences
FIGURE 1: Putative mechanisms of EPO-induced hypertension through its receptors on the endothelial cells, especially in the setting of CKD,
can trigger endothelial dysfunction and vasoconstriction. The NO pathway is severely deranged in response to EPO; ADMA concentrations
increase and cGMP release with NO donors is impaired. Inhibitors of NOS severely elevate BP and provoke mortality in rodents with excess
EPO expression. NO can also trigger ET-1 release, which itself is a potent vasoconstrictor. Prostanoids are downstream to endothelin and there
is a net imbalance favoring vasoconstriction. The effects on the renin–angiotensin system are complex, but in preliminary studies vasoconstric-
tion to angiotensin II is enhanced when patients are given EPO. Similarly, compared with patients not on EPO, vasoconstriction to catechol-
amines is enhanced when patients are treated with EPO. Additional pathways such as volume excess and other mechanisms discussed in the
text are not depicted in the figure.
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were seen [31]. A 2004 study in 41 dialysis patients reported an
increase in mean arterial pressure from 103 to 105 mmHg after
a single injection [32]. Although the change was only 2 mmHg,
it was reported as significant; without a blinded control group,
the likelihood of false discovery is high [32]. A 2013 study used
subcutaneous arteries isolated from a gluteal biopsy from
17 patients with Stage 4 CKD [33]. The response to endothelial-
dependent vasodilatation was tested ex vivo by evaluating
acetylcholine-induced vasodilatation. These blood vessels
were exposed to varying EPO concentrations at 0, 1, 10 and 20
IU/mL [33]. The difference in endothelial function was minimal
when comparing 0 and 1 IU/mL but stark at higher concentra-
tions. However, such higher concentrations are supra-
pharmacologic and it is unclear if they have relevance to EPO
biology. Furthermore, the effects of EPO may be mediated via
endothelin, because using an endothelin type A receptor antag-
onist abrograted the effects of EPO [33].
Endothelin-1
Rats with reduced renal mass have increased endothelin-1
(ET-1) expression in the aorta, mesenteric artery and renal cor-
tex [34, 35]. These rats have increased 24-h urinary excretion of
ET-1 [36]. EPO induces release of ET-1 from endothelial cells in
culture [18, 37]. In contrast to the cell culture experiments, EPO
administered to 5/6 nephrectomized rats does not increase the
circulating concentration of ET-1 despite an increase in BP [38,
39]. This may be because the expression of ET-1 provoked by
EPO is organ specific. EPO-treated rats with reduced renal mass
have no increase in ET-1 in themesenteric artery or renal cortex,
yet the aortic content of ET-1 is increased [39, 40]. The increase
in aortic ET-1 was further augmented by the NO synthase
(NOS) inhibitor L-arginine analog NG-nitro-L-arginine methyl
ester (L-NAME). This suggests that NO has an important effect
on abrogating the expression of ET-1 in large vessels and is an
upstream process [40]. Abrogation of oxidative stress in EPO-
treated nephrectomized rats by tempol also reduces tissue levels
of ET-1, hypertension and renal injury [41]. This suggests that
oxidative stress is also an upstream process to ET-1-generation
in the kidney. However, as discussed below, prostanoids may be
a downstream mediator of ET-1 induced vasoconstriction. Mice
specifically expressing ET-1 in the endothelium, when treated
with EPO even without nephrectomy, have an increase in BP,
impairment of endothelial function, resistance artery remodel-
ing and aortic inflammation and oxidative stress [42]. These
adverse effects can be blocked with exercise over 8 weeks.
Consideration of the tissue-specific expression of endothelin
receptors is needed to appreciate the endothelin biology. Rats
with reduced renal mass have reduced expression of the vasodi-
latory endothelin receptor type B (ETB) in the aorta, mesenteric
artery and renal cortex [34, 35]. Furthermore, in rats with
reduced renal mass, EPO increases the vascular and renal cortex
expression of ETB receptor mRNA [43]. This parallels the
increase in ETB receptor density in the endothelium of rats [43].
Compared with wild-type mice, mice heterozygous for the ETB
receptor have a greater increase in BP with EPO [43]; mice het-
erozygous for the ETA receptor have BP responses that are simi-
lar to wild-type mice. In rats with subtotal nephrectomy and
EPO-induced hypertension, treatment with a selective ETA
receptor antagonist is more effective than placebo in abrogating
the increase in BP [44]. In contrast, the nonselective ETA/ETB
receptor antagonist, bosentan had no effect in preventing EPO-
induced hypertension.
In patients with CKD treated chronically with EPO, ET-1
concentration is increased [45–48]. In a cross-sectional study of
44 end-stage renal disease patients [24 hemodialysis, 20 contin-
uous ambulatory peritoneal dialysis (CAPD)], of which half
were on EPO therapy, plasma ET-1 concentration directly cor-
related with systolic BP [49]. In EPO-treated patients on CAPD,
plasma ET-1 concentrations correleated with mean BP [50].
This correlation is not seen in those not treated with EPO [50].
However, the acute administration of EPO does not increase
ET-1 concentration [31]. Vasoconstriction induced by infusion
of ET-1 is similar in patients with CKD before and after
treatment with EPO, thus the vasoconstriction dose–response
relationship to ET-1 is not altered with EPO-treatment [51].
In summary, treatment of anemia of CKD with EPO
uncovers the endothelial dysfunction through increased pro-
duction of vascular ET-1. Reduced expression of the vasodila-
tory ETB receptor due to genetic heterogeneity or cross talk by
other endothelium-derived vasoactive autacoids such as NO,
prostanoids and angiotensin II may play an important role in
the genesis of EPO-induced hypertension [35].
Prostanoids
Prostanoids play an important role in maintaining vascular
tone and renal sodium handling. Thromboxane A2 (TXA2) and
prostaglandin F2a (PGF2a) have vasoconstrictor activity, whereas
PGI2 is vasodilatory. TXB2 is a stable metabolite of TXA2,
whereas 6-keto-PGF1a is a stable metabolite of PGI2 [37]. In a
2005 study, rats with reduced renal mass who became anemic
and hypertensive as expected also had an increase in vascular
and renal concentration of TXA2 and PGI2 [52]. In these ani-
mals, treatment with EPO further aggravated hypertension and
stimulated vascular and renal TXA2 and PGI2 [52]. Pretreatment
with aspirin blocks both the synthesis of TXA2 and PGI2 and
therefore had no net effect on EPO-induced hypertension [52].
In contrast to systemic exposure of EPO, rabbit aortic rings
incubated with EPO show an increase in TXA2 but a reduction
in PGI2 [18, 37]. In human renal artery in vitro as well as rabbit
aortic rings, incubation with EPO leads to an increase in the
synthesis of constrictor prostanoids such as TXB2 and PGF2a
but a reduction in the vasodilatory prostaglandin PGI2 [53].
However, the concentration of EPO used to incubate these rings
was far beyond the physiological range. TXB2 was increased
and 6-keto-PGF1a unchanged in the aorta of rats with reduced
renal mass treated with EPO [54]. An antagonist of thrombox-
ane, ridogrel, abrogated hypertension in EPO-treated animals
but did not alter the plasma concentration of ET-1 [54]. An
antagonist of ET-1, ABT-627, was even more effective than
ridogrel in treating hypertension; moreover, it also reduced the
concentration of TXB2 in the aorta [54]. Thus prostanoids may
serve as a downstream mediator of vasoconstriction in response
to ET-1 activation. The imbalance in vasoconstrictor to vasodi-
latatory prostanoids may lead to a net increase in vascular
EPO-induced hypertension 1693
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resistance and therefore hypertension. The use of antiplatelet
therapy has been postulated to prevent the development of
hypertension among patients treated with EPO [55]; the mech-
anism of the antihypertensive effect remains unclear.
NO
NO is a potent endothelium-derived vasodilator and plays
an important role in the genesis of hypertension in CKD. NO
has important effects on the endothelium, blood vessels,
kidneys and BP. Each of the effects are discussed below.
Endothelium. In uremia, NO synthesis in the endothelium
is blunted. Suprapharmacologic EPO exposure to endothelial
cells in culture media results in a reduction in endothelial NOS
[56] and high concentrations (such as 10–200 U EPO/mL)
provoke an increase in the NOS inhibitor asymmetric dimethy-
larginine (ADMA) in a dose-dependent manner; this is
accompanied by reduced activity of dimethylarginine dimethy-
laminohydrolase (DDAH) [57]. DDAH is an enzyme that
breaks down ADMA, generating citrulline and dimethylamine,
and is the major mechanism of ADMA removal [58]. In vivo
studies reveal that compared with saline-treated controls, Balb/
c mice with intact kidneys injected with more reasonable expo-
sure to EPO (such as 30 U every other day for 10 weeks) show
ADMA concentrations that were 46% higher [59]. In compari-
son, symmetric dimethyl arginine (SDMA) concentrations are
unchanged. Of note, there is no mechanism of direct synthesis
of ADMA; free ADMA is generated by proteolysis of methy-
lated proteins [58]. Free ADMA can inhibit endothelial cell
NOS and cause endothelial dysfunction and has been linked to
poor outcomes in CKD.
Blood vessels. In rabbit, aortic rings harvested from animals
with intact kidneys, acetylcholine-induced vasodilatation,
which is dependent upon an intact endothelium, was not
blunted when rings were incubated with EPO for 30 min [53].
In sharp contrast, among rats with reduced renal mass, the
release of cyclic guanosine monophosphate (cGMP) by nitrate
donors of aortic rings is augmented. However, this augmenta-
tion is blunted when rats were treated with EPO [60]. The
endothelial and inducible NOS protein mass is reduced in these
rats regardless of EPO treatment, but when treated with felodi-
pine, the protein mass in the aorta is restored. Thus the pres-
ence or absence of renal failure has an important effect on the
role of EPO in blood vessels; calcium-channel blockade may
have at least partially restored the abnormalities.
Kidney effects. Rats with intact renal mass upon treatment
with EPO display an increase in renal NO; this is noted by an
increase in urinary cGMP [61] and urinary nitrates [62]. Rats
with reduced renal mass have a reduction in the urinary nitrate
excretion rate that is further reduced with EPO treatment [63].
The endothelial and inducible NOS protein mass is reduced in
rats with subtotal nephrectomy regardless of EPO treatment,
but when treated with felodipine the protein mass is restored
[63]. When mice with intact renal mass are given EPO,
although ADMA concentrations in plasma are increased, the
urinary excretion of NO metabolites is also increased [59].
Similar findings are seen in rats with intact kidneys treated with
EPO [64]. In fact, mice treated with EPO for 10 weeks have an
increased kidney expression of NOS1 and NOS2 despite the
EPO-induced increase in ADMA [59]. Similarly, rats with
intact kidneys made hypertensive with EPO have increased
urinary excretion of nitrites and nitrates [65]. The renal vasodi-
latory response to acetylcholine (endothelium dependent) and
sodium nitroprusside (endothelium independent) are both
similar to vehicle-treated rats [65]. Thus, reduced renal mass is
necessary to uncover the effects of EPO.
BP effects. Inhibitors of NOS can exacerbate hypertension
in EPO-treated animals even when the renal mass is not
reduced [61]. Among animals treated with EPO, exposure to L-
NAME, an inhibitor of NOS, results in hypertension [40], the
magnitude of which is greater when renal mass is reduced [40].
In rats in whom CKD is induced by ligating renal arteries, the
restoration of endothelial NOS by gene delivery improves NO
release and prevents the development of hypertension [66]. In
rats with reduced renal mass and EPO-induced hypertension,
the treatment of hypertension with felodipine partially restores
the abnormalities in NOmetabolism [63].
The critical importance of NO in EPO-induced hyperten-
sion has been studied in a transgenic mouse model [67].
Transgenic mice overexpressing human EPO were generated.
Despite hematocrit levels of 80%, adult transgenic mice did not
develop hypertension or thromboembolism because of a com-
pensatory increase in endothelial NOS levels, NO-mediated
endothelium-dependent relaxation and circulating and vascular
tissue NO levels. Administration of L-NAME led to vasocon-
striction, an increase in vascular resistance, hypertension and
death of transgenic mice; the wild-type siblings developed
hypertension but did not show increased mortality.
A translational research study elucidated the mechanism of
endothelial dysfunction in 56 patients on hemodialysis treated
with EPO [68]. Endothelial progenitor cells, which the investi-
gators state reflect endothelial cell function, were isolated from
these patients and mRNA levels for both the full EPO receptor
and a spliced, truncated EPO receptor were measured. The
authors note that activation of the full EPO receptor triggers a
signaling cascade that ultimately terminates in cGMP and NO
production and subsequent vasodilation. However, it was
observed that in patients with EPO-induced hypertension there
was a positive correlation with the spliced, truncated variant of
the receptor. This led to the conclusion that the truncated var-
iant of the receptor serves as a dominant negative regulator of
the cGMP/NO cascade, thus blunting vasodilation and possible
downstream hypertension.
From the above it appears that the effects on BP due to EPO
exposure may be mediated by the generation of endothelial
NO. At least there is some evidence for a reduction in NO gen-
eration and blunting of the NO effect on both the kidneys and
vasculature. Transgenic models demonstrate that endothelial
NO appears to be critical in maintaining normotension, pre-
venting cardiovascular dysfunction and survival in vivo in the
setting of EPO use.
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Catecholamines
In rabbit, aortic rings incubated with very high EPO concen-
trations result in increased vasoconstriction when exposed to
norepinephrine [37, 53]. Norepinephrine concentrations were
increased following 12 weeks of EPO treatment in one study
[69] but decreased in another study of Japanese hemodialysis
patients [70]. Vasoconstriction induced by infusion of norepi-
nephrine was increased in patients with CKD after treatment
with EPO, thus the vascular sensitivity to norepinephrine was
increased in human studies [51, 71]. Furthermore, white blood
cell a-2 receptor density was reduced following EPO treatment
[45, 72]. In summary, these data suggest both an elevation of
catecholamines as well as enhanced sensitivity to catechol-
amines on the blood vessels as a mechanism of EPO-induced
hypertension.
Renin–angiotensin–aldosterone system (RAAS)
Eggena et al. [73] evaluated the effects on the RAAS at the
molecular level in Wistar rats upon treatment with EPO. In the
kidney, both renin mRNA and angiotensinogen mRNA were
increased by EPO. In the heart, no alterations in mRNAs were
seen. In the aorta, angiotensinogen-mRNA but not renin
mRNA was elevated. In both the aorta and kidney, a significant
correlation was observed between angiotensinogen mRNA and
BP. In cultured rat vascular smooth muscle cells, Barrett et al.
[74] show that EPO induces an increase in both types of angio-
tensin II receptors, even in the presence of enalapril or losartan.
Among hemodialysis patients, infusion of angiotensin II leads
to excess vasoconstriction, suggesting that angiotensin II sensi-
tivity is increased with EPO treatment [51]. These data suggest
that the vasoconstrictive potential is enhanced with EPO
treatment.
In isolated perfused rodent kidneys, EPO treatment results
in RAAS-stimulated sodium retention [75]. This is in sharp
contrast to normal human volunteers where EPO treatment
caused a reduction in plasma volume, plasma renin activity and
aldosterone [76]. However, in rats with subtotal nephrectomy
treated with EPO, in terms of treatment there is no unique
effect on BP lowering of RAAS blockade. This is because the
reduction in systolic BP was similar when rats were treated
with traditional triple therapy (reserpine, hydralazine and
hydrochlorothiazide) or with the RAAS blockers captopril or
losartan [36].
Despite an increase in mean arterial pressure in 12
Japanese hemodialysis patients treated with EPO, plasma
renin activity was found to be reduced [70]. Among dialysis
patients treated with EPO, a close relationship is seen
between exchangeable sodium, an increase in plasma aldos-
terone and an increase in BP [77]. As discussed above, atten-
tion to dry weight can abrogate EPO-induced hypertension
among dialysis patients.
The above data—both in animals and humans—do not
exclude the possibility of EPO causing hypertension by induc-
ing volume excess or in the setting of volume excess. For exam-
ple, the rodent subtotal nephrectomy models are associated
with volume overload, which may be a prerequisite for develop-
ing hypertension. EPO, as noted above, can provoke sodium
retention as well. However, the quality of the data do not allow
deducing a cause-and-effect relationship.
Blood viscosity
Blood viscosity increases in parallel with blood hematocrit
and has been cited as a mechanism of EPO-induced hyperten-
sion. However, not all patients who have correction of anemia get
hypertensive. Thus the change in blood viscosity by itself appears
to be insufficient to account for EPO-induced hypertension.
Vascular sensing of hypoxia
Breathing 60% oxygen for 10–12 min leads to an increase in
forearm vascular resistance paralleled by a reduction in forearm
blood flow, but not in all patients [78]. This phenomenon is
only observed in those patients in whom BP increases with
EPO treatment [78]. Thus the vascular response to hypoxia—
and its reversal with correction of anemia—may be a funda-
mental mechanism of the genesis of hypertension induced by
EPO.
HYPOXIA-INDUCIBLE FACTORS: PROLYL
HYDROXYLASE INHIBITORS
EPO gene expression is provoked by hypoxia-inducible tran-
scription factors (HIFs) [79]. HIF-a subunits are oxygen
labile and, under normal oxygen tension, oxidized by prolyl
hydroxylases. Inhibitors of prolyl hydroxylases can stabilize
HIFs, simulate hypoxia and promote erythropoiesis [79].
HIF stablizers not only stimulate EPO, but also many other
genes responsible for angiogenesis, tumor growth, cell prolif-
eration and metabolism. HIF stablizers may aggravate
hypertension by several mechanisms. For example, chronic
intermittent hypoxia through HIF signaling in the carotid
artery is thought to provoke systemic hypertension [79]. A
2016 study in in vitro and in vivo rodent models shows that
hypoxia induces inorganic phosphorus–induced vascular
smooth muscle calcification [80]. In this rodent model, roxa-
dustat, an oral HIF prolyl hydroxylase inhibitor, enhanced
vascular calcification [80]. The downstream effect of long-
term use may therefore be hypertension. Vascular calcifica-
tion is common in CKD and contributes to arterial stiffness.
Increased arterial stiffness is strongly associated with ele-
vated interdialytic ambulatory blood pressure [81]. On the
other hand, HIF stablizers may raise EPO to more physio-
logic levels, reduce cross talk with vascular EPO receptors
and mitigate hypertension. A 2014 study demonstrated that
compared with EPO, treatment with the HIF stabilizer moli-
dustat corrected anemia associated with subtotal nephrec-
tomy, but in contrast to EPO, it reduced systolic BP in a
dose-dependent manner [82]. The authors postulate that
anti-inflammatory and antifibrotic effects of the drug on the
kidney may be operative. This study further illustrates that
increases in hematocrit can be dissociated from an increases
in blood pressure.
Several HIF stablizers are in Phase 3 clinical trials for the
treatment of anemia in CKD. The ongoing Phase 3 trials of HIF
stabilizers are evaluating, among patients with CKD, the equiv-
alence of hemoglobin increase from baseline compared with
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approved EPO-stimulating agents. Whereas hypertension is
not a primary outcome measure for these Phase 3 trials, the
equivalence of the cardiovascular outcomes is an important
safety endpoint.
Human data are available but are inadequate to address
the question of hypertension with HIF stablizers. Among 145
patients with CKD not on dialysis who were treated with rox-
adustat for 16–24 weeks in varying doses, hypertension was
reported in 11 (7.6%) [83]. Among 60 incident dialysis
patients treated with roxadustat for 12 weeks, hypertension
requiring an escalation of antihypertensive therapy occurred
in 6 (10%) [84]. In the above studies, there was no placebo
group or a group treated with EPO alone, therefore, whether
the drug is equivalent to, safer or more detrimental than EPO
or placebo with respect to hypertension remains unclear. In a
2017 study in China, among 61 CKD patients treated with
roxadustat over 8 weeks, 4 (7%) developed hypertension
compared with none of 30 treated with placebo [85]. In the
same report, among 74 patients on dialysis treated for 6
weeks, 3 (4%) developed hypertension compared with 1 of 22
(5%) treated with EPO [85]. In a 2016 study of vadadustat
among nondialysis CKD patients treated for 20 weeks, 138
were assigned to vadadustat and 72 to placebo; 11 in the
vadadustat group (8%) and 2 in the placebo group (2.8%) had
hypertension reported as an adverse event.
CONCLUSIONS
In summary, mediated by a variety of molecules, there is an
imbalance in the vascular tone favoring net vasoconstriction
that mediates hypertension due to EPO, especially in the setting
of CKD. Besides the direct effects of the prostanoids,
endothelins and NO pathways, EPO administration is also asso-
ciated with increased responsiveness to catecholamines and
angiotensin II and mitigation of hypoxia-induced vasodilata-
tion responses. EPO-induced hypertension, at least in part,
appears to be independent of an increase in hemoglobin,
because experiments show that hemoglobin may be increased
by EPO without an increase in BP by simply treating the ani-
mals with EPO binding protein and that treatment with EPO in
the setting of iron deficiency may not increase hemoglobin but
may still increase BP. However, experimental data are not con-
sistent across studies and better mechanistic designs are needed,
especially in people with CKD, to dissect the precise mechanism
of EPO-induced hypertension. Animal studies suggest that HIF
stablizers may provoke hypertension and those with high phos-
phorus concentrations and sleep apnea may be at an increased
risk. Others show that there may be an antihypertensive effect
via kidney repair. Whether this class of drugs will reduce
the risk of hypertension compared with EPO remains to be
seen.
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